Ongoing

Biomedical Translation Fund (BTF)

Funding

$250,000,000 - $501,250,000

Region

Commonwealth

View Official Page

Overview

An equity co-investment venture capital program that provides early-stage biomedical companies with investment to develop and commercialise biomedical discoveries. The fund supports therapeutic, medical, pharmaceutical products, processes, services, technologies and procedures that improve health and wellbeing through prevention, diagnosis and treatment.

Eligibility Requirements

Early-stage biomedical companies with average annual revenue below $25 million per year, majority of employees and assets in Australia, ABN, incorporation under Corporations Act 2001, and working on or planning to work on a biomedical discovery. Applications are made directly to one of three licensed private sector fund managers who make investment decisions.

Who Can Apply

Startups

Relevant Industries

HealthBiomedicalPharmaceutical

How to Apply

Applications are submitted through the official government portal. Review the eligibility criteria carefully before applying, and ensure all supporting documents are prepared.

Visit the official application page

Disclaimer: Grant information is sourced from official government websites and updated regularly. Always verify current eligibility and deadlines on the official program page before applying.

Related Grants

Ongoing·Commonwealth·Up to $500,000,000

Biomedical Translation Fund

The Biomedical Translation Fund provides capital to support groundbreaking innovation in Australia, helping commercialize research from universities and research organizations into commercial products. The fund pools $500 million in total capital ($250 million from the federal government and $250 million from private investors) to support venture capital managers in taking Australian biomedical innovations through the commercial pathway.

Ongoing·Commonwealth

Early Stage Venture Capital Limited Partnerships (ESVCLPs)

A venture capital program that provides capital and professional expertise to innovative Australian early-stage companies and high-growth startups. The program offers increased fund sizes up to $200 million, a 10% tax offset on capital deployed into start-up companies, and a tax-exempt environment for investment returns.

Ongoing·Commonwealth·$800,000 - $19,200,000

Blood Borne Viruses (BBV) and Sexually Transmissible Infections (STI) Research Program

This grant program is delivered, in part, through the collection of data, ongoing surveillance, and pertinent research and evaluation activities related to the BBV and STI outlined in the National BBV and STI Strategies, namely: National Hepatitis B Strategy National Hepatitis C Strategy National STI Strategy National Aboriginal and Torres Strait Islander BBV and STI Strategy National HIV Strategy. The Department’s First National BBV and STI Research Strategy 2021-2025 and its future iterations (the National BBV and STI Research Strategy), sets out the aims and objectives for the multi-disciplinary research activities undertaken within Australia and supports the implementation of the related National BBV and STI Strategies. By enabling and focussing on the conduct of BBV and STI research, the Research Strategy aims to identify challenges, barriers and opportunities to achieve the agreed national goals and targets of the National BBV and STI Strategies. The Research Strategy also contai